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ABSTRACT 
Parkinson’s and Alzheimer’s disease are the two most common neurodegenerative diseases 
world-wide, but are still little understood. Papers in this thesis examine some of the possible 
pathogenic mechanisms with the help of mouse models and analysis of human post-mortem 
tissue. 
Gene-based animal models have been developed to study pathological pathways during disease 
progression. Using mouse models with overexpression or ablation of disease-related genes we 
analyzed effects of pathogenic mutations on the function of the proteins. A prominent feature 
of patients carrying the G2019S mutation in leucine rich repeat kinase 2 (LRRK2) is a high 
load of Lewy Bodies, an intracellular protein accumulation highly enriched in α-synuclein. We 
investigated the interaction of LRRK2 and α-synuclein in transgenic mice and did not find an 
influence of LRRK2 expression on fibrillization of α-synuclein or dopamine neurons 
pathology, indicating separate pathways for the two genes causing PD.  
Using another genetic model with a conditional knockout of the mitochondrial transcription 
factor A in dopamine neurons, the MitoPark mouse, we detected reduced dopamine release and 
pacemaker activity in the substantia nigra several weeks before these mice develop motor 
dysfunction. The mRNA levels of the hyperpolarization-activated cyclic nucleotide gated 
channels 1-4 (HCN1-4), responsible for the pacemaking activity, were not altered in MitoPark 
mice, indicating that post-translational modifications occur early in the presymptomatic stages 
of Parkinson’s disease. 
To evaluate behavioral and cellular changes related to L-DOPA therapy we used older 
MitoPark mice, which model late stages of Parkinson’s disease. Chronic L-DOPA treatment 
normalized gait parameters but induced also progressing dyskinetic behavior in MitoPark mice. 
The treatment also caused a robust increase of TH mRNA expression in the striatum, as 
evidenced by RNA-Sequencing. The induction of TH in striatal neurons with an interneuronal 
phenotype was dependent on the degree of dopamine depletion and the L-DOPA dose. 
In disease-affected brain areas of patients with Parkinson’s or Alzheimer’s disease we found a 
significant increase in small-sized cells expressing the lysosomal enzyme myeloperoxidase. 
This finding supports involvement of a neuroinflammatory component in these diseases and 
encourages the research for anti-inflammatory treatments. Another protein implicated in the 
pathogenesis of neurodegeneration is the serine peptidase HTRA2. We detected altered enzyme 
activity and expression of HTRA2 in frontal cortex samples from Alzheimer’s disease patients. 
The association of a mutation in a HTRA2 allele with Alzheimer’s disease in our case-control 
material further supported a role of mitochondrial dysfunction in the pathology.  
Taken together, the studies presented in this thesis uncover changes in gene and protein 
expression in mouse and human samples, as well as behavioral changes in animal models of 
disease and will aid the development of better treatment options by increasing our knowledge 
of underlying pathological mechanisms. 
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INTRODUCTION 
Common features of many neurodegenerative diseases are aberrant or misfolded proteins, 
ubiquitin-proteasome system defects, oxidative stress, and mitochondrial perturbation, which 
all can result in cell death. Genetic mutations and certain environmental factors also increase 
the risk of developing a neurodegenerative condition. Familial forms are rare monogenic 
diseases and typically have an earlier onset than sporadic forms. In some cases, different 
neurodegenerative diseases are even linked to the same polymorphisms or mutations, thereby 
sharing similar pathological mechanisms. In the following, the two most common 
neurodegenerative diseases, Parkinson’s disease (PD) and Alzheimer’s disease (AD) will be 
described in more detail. 
PARKINSON’S DISEASE 
Parkinson’s disease (PD) has a prevalence of about 1% at the age of 65 years increasing to 5% 
at the age of 85 years. Men are slightly more affected than women (Hirtz et al., 2007). 
PD was first described in 1817 by James Parkinson in “An Essay on the Shaking Palsy” 
(Parkinson, 2002), but had been known since 4500 BC in Ayurveda as Kampavata and was 
treated with ground seeds of Mucuna pruriens in ancient India (Manyam, 1990, Ovallath & 
Deepa, 2013). Kampa means tremor, which is the most prominent symptom occurring during 
rest and later gave rise to the name shaking palsy. Other than tremors, the cardinal symptoms 
are bradykinesia, postural instability, and rigidity. These motor symptoms are preceded by 
more unspecific non-motor symptoms such as constipation, olfactory dysfunction, sleep 
disturbances, or psychological symptoms such as depression (Klockgether, 2004). The disease 
starts slowly as neuronal dysfunction originating from the death of dopaminergic (DA) cells of 
the substantia nigra pars compacta (SNc) (Fearnley & Lees, 1991). More than half of the DA 
neurons have typically died when patients first contact a physician because of motor symptoms, 
which typically occur unilaterally in the beginning due to the unsymmetrical degeneration of 
DA SNc neurons (Fearnley & Lees, 1991). Dementia can be an early complication of PD but 
increases to 78% later on (Aarsland et al., 2003). Biomarkers to detect the disease before motor-
symptom onset have not been found yet, and are an important research topic. 
Pathology 
Although the loss of SNc neurons has been the focus of most studies, the first lesions might 
occur in neurons of the wall of the gastrointestinal tract, the dorsal motor neurons in medulla 
oblongata, neurons in the raphe nucleus and locus coeruleus (Braak et al., 2003, Del Tredici et 
al., 2002, Kupsky et al., 1987). A hallmark of affected neurons are proteinaceous inclusions 
termed Lewy bodies (LBs) and Lewy neurites consisting of many proteins with α-synuclein as 
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a prominent component (Lewy, 1912, Spillantini et al., 1997). LB pathology is believed to 
spread from the brainstem via the basal forebrain to cortex cerebri as the disease progresses 
(Braak et al., 2003). The detection of LBs is however not essential for the diagnose of PD, as 
they are not found in all PD patients, and can be detected in the amygdala of patients with AD, 
and also neurologically healthy controls (Fearnley & Lees, 1991, Hamilton, 2000). 
Neurofibrillary tangles consisting of tau protein and Aβ plaques are detected in 15% of all PD 
brains and correlate with dementia (Compta et al., 2011, Jellinger, 2007, Jellinger & Attems, 
2008). The partly overlapping pathologies of neurofibrillary tangles, LBs, and Aβ plaques hint 
to similar pathways in neurodegeneration, although the cellular distribution varies between the 
diseases. 
A further common pathological feature is chronic inflammation in affected brain regions in AD 
and PD. This process may be triggered by degeneration, in AD even preceding the stage of 
aggregated proteins, and contribute to disease progression. Results from mouse models suggest 
that neuroinflammation in AD occurs even before the detection of aggregated proteins (Heneka 
et al., 2005). Activated astrocytes and especially microglia release proinflammatory cytokines, 
free radicals, chemokines, members of the complement cascade, as well as inflammatory 
enzymes. The activation of microglia may also impair the function of endothelial cells, damage 
the blood-brain barrier and allow the entrance of leukocytes (Brochard et al., 2009, Togo et al., 
2002, Yenari et al., 2006). Leukocytes contain the enzyme myeloperoxidase (MPO), which has 
been shown to be increased in brain tissue in PD and AD (Choi et al., 2005, Green et al., 2004). 
MPO is expressed in the myelocytic lineage until the stage of promyelocytes in the bone 
marrow. It is held in lysosomes of monocytes, as well as in the azurophilic granules of 
neutrophil granulocytes which play a role in the microbicidal defense (Borregaard & Cowland, 
1997). During the respiratory burst it is released from the granules and produces cytotoxic 
hypochlorous acid (HOCl) (Harrison & Schultz, 1976). It has been reported to be expressed in 
microglia, astrocytes, neurons and plaques in hippocampus and cortex of AD patients and 
microglia in the midbrain of PD patients (Choi et al., 2005, Green et al., 2004, Maki et al., 
2009, Reynolds et al., 1999).  
Another supporting factor for the role of inflammation in neurodegenerative diseases is that 
non-steroidal anti-inflammatory drugs slightly reduce the risk of PD (Etminan et al., 2003, 
Samii et al., 2009). 
Causes 
Already in 1880, Leroux discovered a familial aggregation of parkinsonism previously 
believed to be sporadic (Leroux, 1880). A Swedish family with mendelian Parkinson was 
reported in 1949 and later the cause was shown to be duplications and triplications of α-
synuclein (Mjönes, 1949, Puschmann et al., 2009). Twin studies strengthened genetic causes 
of neurodegeneration and in 1997 the first gene causing familial PD, α-synuclein, was mapped 
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by linkage studies (Duvoisin & Johnson, 1992, Polymeropoulos et al., 1997). It was termed 
PARK1 and in the following years further genes and loci were mapped. In the group of sporadic 
PD cases there might be many with a genetic cause that has not been identified yet due to 
methodological limitations or polygenetic inheritance.  
Incomplete penetrance of mutations may hint to an interplay of the genetic variation with other 
genetic or environmental factors. Langston and coworkers discovered one environmental factor 
and described the fast development of parkinsonian symptoms in young drug addicts using 
contaminated “synthetic heroin” (Langston et al., 1983). This contained 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) which can cross the blood-brain barrier and is converted to 
1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B (MAOB) (Markey et al., 
1984). MPP+ is transported into cells harboring the DA transporter (DAT). Inside cells MPP+ 
accumulates in mitochondria and inhibits complex I of the electron transport, which leads to 
the reduced production of ATP, the production of reactive oxygen species and eventually to 
cell death (Ramsay & Singer, 1986, Sinha et al., 1986). Other risk factors such as traumatic 
brain injuries have received much attention in the last years after the diagnosis of PD in 
individuals who have had head injuries, for example boxers, football, and ice hockey players 
(Goldman et al., 2006). Another new area of research in PD is epigenetics. Without modifying 
the genome, epigenetic modifications may alter risk or susceptibility to environmental factors 
(reviewed in (Ammal Kaidery et al., 2013)).  
In addition to α-synuclein, detoxifying enzymes attracted attention in reaction to the discovery 
of PD inducing toxins. An important role of mitochondria emerged not only due to the impact 
of toxins on mitochondria but also by findings that genes involved in familial PD including 
parkin, PINK1 and DJ-1, are involved in the maintenance of a healthy pool of mitochondria. 
Several different features can be affected in mitochondrial homeostasis in PD. Mitochondrial 
motility may be impaired by mutations or alterations of expression in PINK1, Parkin, α-
synuclein or leucine-rich repeat kinase 2 (LRRK2), as these proteins all interact with the 
microtubule-mediated trafficking of mitochondria in the cell (Gillardon, 2009, Lee et al., 2006, 
Weihofen et al., 2009, Yang et al., 2005). Dynamic fusion and fission of mitochondria is also 
needed to maintain critical mitochondrial functions and altered expression of PINK1, for 
example, increases the amount of dysfunctional mitochondria in cell culture studies (Yang et 
al., 2008).  
Mitochondria supply energy to the cell in the form of adenosine triphosphate (ATP), which is 
generated by the respiratory chain in the inner mitochondrial membrane. The organelles contain 
their own DNA (mtDNA) and 13 of the 37 genes in mtDNA encode subunits of the respiratory 
chain and 24 encode the translational machinery in the mitochondrion. Mitochondria undergo 
regulated turnover, called mitophagy and mtDNA replication is therefore a continuous process 
in both dividing and non-dividing cells. Throughout life mutations and deletions in mtDNA 
accumulate and can cause functional impairment in SNc DA neurons and other cells (Bender 
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et al., 2006). Dysfunctional mitochondria may lead to increased reactive oxygen species (ROS) 
being formed, which in turn damages mtDNA by oxidation (Miquel, 1992).  
Mutations in the mtDNA polymerase γ (POLG), the enzyme responsible for the synthesis and 
proofreading of mtDNA, have been found in idiopathic PD (Luoma et al., 2007). The MitoPark 
mouse models the consequences of impaired mitochondrial function in DA neurons by genetic 
removal of the mitochondrial transcription factor A (Tfam) in these cells, leading to progressive 
degeneration of SNc DA neurons and resulting PD-like motor deficits (Ekstrand et al., 2007). 
Treatment 
The seeds of Mucuna pruriens, which were used in ancient India to treat PD, contain L-3,4-
dihydroxyphenylalanine (L-DOPA), which was isolated in 1937 (Damodaran & Ramaswamy, 
1937, Manyam, 1990). The oral treatment with this DA precursor is still the gold standard 
treatment, as there is no cure or prevention for PD. L-DOPA can cross the blood-brain barrier 
where it is taken up and converted to DA by L-amino acid decarboxylase (AADC) to increase 
the striatal DA content (Lloyd et al., 1975). It is administered together with a peripheral AADC 
inhibitor to limit adverse effects of circulating DA (Cotzias et al., 1969). The effect of L-DOPA 
on motor performance lasts a few hours in the first several years of treatment. With prolonged 
administration, decreased efficiency of L-DOPA treatment and negative side effects, such as 
dyskinesia, pathological gambling and psychotic behavior is observed (Barbeau, 1969, 
Weintraub et al., 2010).  
Dyskinetic symptoms are highly debilitating side effects and eventually limit the use of L-
DOPA, in a third of all patients after about five years after the onset of motor symptoms 
(Ahlskog & Muenter, 2001, Chapuis et al., 2005). The side effects occur more often in early 
onset PD (Fabbrini et al., 2007). The probability of developing dyskinesias increases with 
higher dose of L-DOPA as well as a longer treatment duration (Zappia et al., 2005). L-DOPA 
induced dyskinesias (LID) are choreic movements, small amplitude, dance-like, or dystonic 
movements, a twisting of the limbs due to involuntary contraction of muscles, or a combination 
of both types (Fabbrini et al., 2007). These side effects are coupled to peak plasma levels of L-
DOPA after administration (Tolosa et al., 1975). To avoid the pulsatile L-DOPA plasma 
concentrations, the administration of a L-DOPA gel via an intestinal pump has been developed. 
The treatment has been demonstrated to be effective in advanced PD, but carries the 
disadvantages abdominal surgery and technical problems including dislocation or blocking of 
the catheter and intestinal perforation or obstruction (Fernandez et al., 2014, Fernandez et al., 
2013). 
Drug treatments to increase presynaptic DA include inhibitors of MAOB or catechol-O-
methyltransferase (COMT), enzymes which catalyze DA breakdown. In the past few years an 
initial therapy with DA agonists instead of L-DOPA has been examined in greater detail with 
various results (Group et al., 2014, Parkinson Study, 2000). Deep brain stimulation of the 
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subthalamic nucleus or the globus pallidus pars interna has proven to be effective in advanced 
PD, when drug therapy no longer improves symptoms (Deep-Brain Stimulation for Parkinson's 
Disease Study, 2001).  
Another treatment option, which is still in the experimental phase is the implantation of cells 
that are reprogrammed to functional DA neurons. The first engraftment of DA-cell rich 
fragments of human embryos into PD patients was performed in 1988 and was constantly 
improved to be able to use the patient’s own cells for implantation in the future (Hartfield et 
al., 2014, Lindvall et al., 1988). This research also led to the discovery of new possible 
pathological pathways, such as a prion-like spreading of α-synuclein into before unaffected 
cells in culture and that genetic predisposition increases the susceptibility of reprogrammed 
cells to degenerate (Reyes et al., 2014, Sanchez-Danes et al., 2012). 
ANIMAL MODELS OF PARKINSON’S DISEASE 
The discovery that certain toxins caused parkinsonian symptoms led to the first animal models 
of PD. The most common model is generated by stereotactic injection of 6-hydroxydopamine 
(6-OHDA) into the rat brain to cause degeneration of DA neurons (Ungerstedt, 1968). A feature 
of this model is the possibility to generate a strictly unilateral loss of the uncrossed nigrostriatal 
DA system. The description of parkinsonian symptoms in drug users injecting contaminated 
heroin led to the development of new PD animal models based on systemic poisoning with 
MPTP to cause neurodegeneration (Langston et al., 1983). Dependent on the administration 
regimen, acute, subacute or chronic, different lesion grades modeling different disease stages 
can be achieved. Due to the systemic injection, the DA lesion is bilateral and produces motor, 
as well as non-motor symptoms (Anderson et al., 2007, Fifel et al., 2014, Fredriksson & 
Archer, 1994, Ogawa et al., 1985). Toxin-induced models display a fast DA depletion, whereas 
the slowly degenerating phenotype of PD is more difficult to model. In addition, the injection 
can lead to side effects not related to PD. More recently, the discovery of genetic mutations as 
a cause for PD have led to the generation of transgenic rodent models. These models are based 
on mutations found in familial PD, as well as on mutations found in candidate genes of sporadic 
PD. With the possibility to choose cell-specific promoters, the expression of a transgene can 
be directed to different brain areas. Transgenic animals are generally used to study pathological 
mechanisms of the mutation and most models actually fail to recapitulate motor- and non-motor 
features of PD. Mitochondrial dysfunction found in PD strengthens the implication of 
mitochondria-related genes in pathogenic mechanisms. Since no animal model has been 
developed yet that recapitulates all features of PD, the most relevant model needs to be chosen 
to address each experimental question. 
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Animal models of PD used in this thesis 
The 6-OHDA model 
The 6-OHDA rat model is the oldest and most often used model to study PD pathology. It was 
first described in 1959 and used for the modeling of PD in animals in 1968 (Senoh & Witkop, 
1959, Ungerstedt, 1968). 6-OHDA is an analogue of catecholamines and taken up into the cell 
via DAT and the noradrenaline transporter (Luthman et al., 1989). To exert its toxic effect only 
on DA cells it is often used together with a noradrenaline reuptake inhibitor. It is systemically 
toxic, cannot cross the blood-brain barrier and has to be injected into the brain by stereotaxic 
surgery. Following uptake into the cell, it accumulates and is oxidized, generating hydrogen 
peroxide, which leads to the production of reactive oxygen species and cell death (Cohen, 1984, 
Jeon et al., 1995). Like MPTP, it is toxic to complex I of the electron transport chain (Cleeter 
et al., 1992). Depending on the site of injection and concentration of 6-OHDA, different 
degrees of DA depletion are produced. Injection into the medial forebrain bundle causes 
extensive lesion, into the striatum a slow, progressive and partial lesion, and into the SNc a 
more specific lesion (Francardo et al., 2011, Sarre et al., 2004, Sauer & Oertel, 1994). A 
bilateral lesion, though more closely related to PD in humans, is not often used as it impairs 
the survival of the animal and requires intense care (Cenci et al., 2002, Ungerstedt, 1971). The 
severity of a lesion can be assessed by injections of apomorphine or amphetamine and results 
in turning behavior when a certain degree of striatonigral neurons is destroyed (Hefti et al., 
1980). Other regions, for example the lower brain stem, are not affected by 6-OHDA and cells 
do not show a LB pathology. Motor symptoms, such as akinesia and tremor, are seldom 
reported in the unilateral model, but non-motor symptoms as cognitive deficits, depression-like 
behavior and cognitive impairment, have been detected (Branchi et al., 2008, Lindner et al., 
1999, Tadaiesky et al., 2008). The unilateral 6-OHDA model is suited for the preclinical testing 
for antiparkinsonian drugs (Ilijic et al., 2011). The fast DA depletion does not give time to 
assess the slowly progressing motor impairment and the molecular changes happening before 
the onset of motor symptoms. In most studies, the unlesioned hemisphere is used as the control, 
but in these studies the authors do not take into account the compensatory effects elicited by 
the unlesioned hemisphere (Kozlowski et al., 2004, Morin et al., 2013, Terzioglu & Galter, 
2008). 
α-Synuclein transgenic mice 
The first PARK gene, α-synuclein, was found and mapped in 1997 in an Italian kindred, as 
well as in Greek families with autosomal dominant PD (Polymeropoulos et al., 1997). In 
addition to point mutations, also duplications and triplications of the wild-type α-synuclein 
gene have been shown to cause disease (Farrer et al., 2004, Nishioka et al., 2006). Patients with 
α-synuclein mutations have an autosomal dominant inheritance, an early onset and rapidly 
progressing disease. α-Synuclein is concentrated at presynaptic nerve terminals and 
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accumulates to form the main component of LBs (Jakes et al., 1994, Spillantini et al., 1997). 
The protein is unfolded in its native state but can bind to many ligands and proteins which leads 
to its folding (Deleersnijder et al., 2011, Weinreb et al., 1996). Several possible pathogenic 
mechanisms of A53T α-synuclein have been discovered as for example the inhibition of 
tyrosine hydroxylase (TH) activity in cell culture (Perez et al., 2002). The A53T mutation is 
located in the N-terminal α-helix domain and is in cell culture toxic to catecholaminergic 
neurons and impairs protein degradation via ubiquitinylation (Petrucelli et al., 2002, Stefanis 
et al., 2001). It forms dimers and oligomerizes fast (Conway et al., 2000, Krishnan et al., 2003). 
The insoluble fibrils accumulate and form a part of LBs and Lewy neurites (Irizarry et al., 1998, 
Wakabayashi et al., 1997). α-Synuclein inclusions occur not only in SN DA neurons, but also 
in locus coeruleus, the dorsal vagal nucleus, and the enteric nervous system and oligomeric, 
soluble α-synuclein can be detected in human blood plasma and postmortem cerebrospinal fluid 
and is increased in plasma of patients with PD (El-Agnaf et al., 2003, El-Agnaf et al., 2006, 
Hughes et al., 1992, Wakabayashi et al., 1990).  
One of the α-synuclein models is the A53T α-synuclein overexpressing transgenic mouse under 
the control of the mouse PrP promoter (Lee et al., 2002). In this model, human mutated α-
synuclein mRNA is expressed throughout the brain with a predominant expression in neurons, 
including SNc neurons, and with the protein present mostly in presynaptic terminals. Some, 
but not all, LB containing neurons undergo neurodegeneration. These mice have a late onset of 
motor symptoms, such as reduced spontaneous activity, and die prematurely due to the 
degeneration of neurons (Lee et al., 2002, Martin et al., 2006, Von Coelln et al., 2006). 
G2019S LRRK2 transgene and LRRK2 knockout 
Funayama and coworkers found by linkage analysis a new locus being associated with PD in 
a Japanese family with autosomal dominant PD, which they termed PARK8 (Funayama et al., 
2002). Later, mutations in LRRK2 were found to be the cause (Paisan-Ruiz et al., 2004, 
Zimprich et al., 2004). Patients with LRRK2 mutations have autosomal dominant heredity with 
a late disease onset which does not differ from the idiopathic form (West et al., 2005). LRRK2 
is an protein with 6 domains and the most common mutation G2019S, accounting for about 3-
6% of the familial PD cases and 1-2% of the sporadic cases, is related to an increase in kinase 
activity (Di Fonzo et al., 2005, Gilks et al., 2005, Kachergus et al., 2005, Nichols et al., 2005, 
West et al., 2007). Most of the postmortem brains of G2019S LRRK2 patients contain LBs 
(Wider et al., 2010). 
In vitro studies have indicated that α-synuclein is a phosphorylation target of LRRK2 and that 
it might be implicated in the formation of LBs, as C-terminal epitopes of LRRK2 were detected 
in the halo of some LBs in the midbrain (Greggio et al., 2006, Qing et al., 2009). Furthermore, 
α-synuclein has been suggested to be a phosphorylation target of LRRK2 and a polymorphism 
in α-synuclein may modify the penetrance of LRRK2 mutation carriers in decreasing the age 
at onset (Botta-Orfila et al., 2012, Qing et al., 2009). 
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In paper I two LRRK2 mouse models were used for the analysis of interaction of LRRK2 with 
A53T α-synuclein. 
A mouse model overexpressing human G2019S LRRK2 under the control of a CMV-enhanced 
human platelet-derived growth factor β-chain (CMVE-PDGFβ) was generated (Ramonet et al., 
2011). Aged G2019S LRRK2 mice display 18% reduction of SNc DA neurons, but unchanged 
density of TH positive nerve endings in striatum and unchanged levels of DA. The locomotor 
activity in aged G2019S LRRK2 mice is not impaired. Though no influence on behavior or 
histological level could be detected except for the SNc degeneration, electron microscopy 
revealed autophagic vacuoles in the cell body and axons, as well as abnormal condensed 
mitochondria (Ramonet et al., 2011). 
Mice with deletion of parts of exon 39 and all exon 40 of LRRK2, thereby disrupting LRRK2 
function, were previously described (Andres-Mateos et al., 2009). Brain development is not 
impaired, numbers of SNc neurons and TH immunoreactivity in the striatum are not changed 
in these mice. Likewise, levels of DA, serotonin and their metabolites are unchanged in 
different brain regions. In general, the LRRK2 knockout neither influences DA neuron 
degeneration, nor does it induce other features of PD under physiologic conditions in this model 
(Andres-Mateos et al., 2009). 
The MitoPark mouse model 
The impairment of mitochondria was considered to be relevant to PD pathology before the first 
mutation in a gene causing PD was found and can happen at several different levels. Deletions 
in the mtDNA in SNc neurons of patients with PD were detected, though it was also reported 
that the number of deletions increased with age in neurologically healthy controls (Bender et 
al., 2006). Neurons in the SNc are particularly affected by mtDNA deletions, as the frequency 
of mtDNA deletions was less in putamen and frontal cortex of PD patients (Bender et al., 2008). 
Mitochondrial DNA encodes for 37 genes, of which 13 are respiratory-chain subunits. The 
subunits are part of complexes I, III, IV and V; only complex II is entirely encoded by nuclear 
DNA. The transcription requires several factors, which are encoded both by mitochondrial and 
nuclear DNA. One of these factors is the nucleus-encoded mitochondrial transcription factor A 
(Tfam), which binds to the mtDNA and promotes transcription (Dairaghi et al., 1995). It also 
regulates mtDNA stability, replication and copy number and a homozygous systemic knockout 
is embryonically lethal (Clayton, 1991, Ekstrand et al., 2004, Larsson et al., 1998, Wang et al., 
2001). In these homozygous knockout embryos, the mtDNA is severely reduced, as is oxidative 
phosphorylation, leading to apoptotic cell death.  
In MitoPark mice, Tfam is specifically knocked out in DA cells expressing DAT. The 
expression of DAT starts in the rat during embryonic development (Coyle, 1973). DAT mRNA 
in the mouse is expressed in SNc neurons, and much less expressed in parts of the VTA 
(Sanghera et al., 1994). 
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MitoPark mice are generated by crossing two mouse strains: mice in which loxP-sites are 
inserted before exon 6 and after exon 7 of the Tfam gene, and mice expressing the cre-
recombinase under the DAT promoter (Ekstrand et al., 2007, Larsson et al., 1998). Crossing 
DAT-cre mice with loxP-flanked Tfam mice leads to the disruption of Tfam in DA SNc 
neurons (Ekstrand et al., 2007). As expected from previous studies, the mtDNA expression is 
severely reduced and the expression of COX subunit I mRNA is decreased already at the age 
of 6 weeks with a decrease of its enzyme activity found in 20-week-old mice. The DA cell loss 
in SNc is slowly progressive and corresponds with a decrease of DA levels in SN, VTA and 
cortex. Dysfunctional mitochondria resembling inclusion bodies observed in DA neurons in 
MitoPark mice do not stain for α-synuclein (Ekstrand et al., 2007). In accordance with the 
decreasing DA levels in striatum, decreased vertical activity is detected at the age of 12 weeks 
and horizontal activity at the age of 24 weeks, modeling the early postural instability and 
bradykinesia in PD patients. The response to L-DOPA is DA depletion dependent in MitoPark 
mice (Ekstrand et al., 2007, Galter et al., 2010).  
Dopaminergic neurons express TH and immunostaining for this protein allows histological 
study of these cells. For the electrophysiological study these neurons can either be made visible 
by the intracellular expression of a fluorescent protein or by a large amplitude, slowly activated 
current (hyperpolarization-activated current, Ih) that does not inactivate after prolonged 
membrane hyperpolarization (Lacey et al., 1989). The molecular basis for this Ih current is 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (Ludwig et al., 1998). In 
the heart, If, the correlate of the brain Ih, is described as a “pacemaker”, which is activated by 
hyperpolarization and shows slow kinetics (Brown & Difrancesco, 1980, Difrancesco, 1993). 
Ih exerts stabilization on the resting membrane potential and influences the input resistance 
(Chen et al., 2001, Magee, 1998). In the SNc, it distinguishes DA from non-DA cells, but the 
importance of HCN channels for the pacemaking activity has been shown to decrease three 
weeks after birth (Chan et al., 2007, Lacey et al., 1989). There are four known isoforms, HCN1 
to 4, which display differential expression patterns in the rodent brain. HCN1 is mainly 
expressed in neocortex, hippocampus, cerebellar cortex and brain stem. HCN2 is ubiquitously 
expressed with the highest expression in thalamus and brain stem. HCN3 is expressed only at 
a low level in the brain and HCN4 is most highly expressed in thalamus, olfactory bulb and the 
medial habenula (Notomi & Shigemoto, 2004, Santoro et al., 2000). 
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ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting about 5% 
of the people at the age of 65 and up to 30% of people over the age of 85 (Galimberti & Scarpini, 
2013). It is the most common form of dementia, accounting for more than half of all cases. 
Because of the increase in life expectancy, the number of people with dementia is believed to 
increase with a projection of up to 81 million in 2040, thereby increasing the costs for medical 
treatment and care (Ferri et al., 2005). 
The disease was described by the Bavarian psychiatrist Alois Alzheimer in 1906 with the 
neuropathological phenotype and the known hallmarks of the disease, plaques, tangles and 
memory deficits, though senile dementia was known since the ancient Greeks and Romans 
(Berchtold & Cotman, 1998). During disease progression episodic memory declines, aphasia 
develops and judgment, decision-making and orientation are impaired. In the brain of aged 
individuals plaques and tangles are formed before the clinical onset of symptoms (Davies et 
al., 1988). The pathology starts in the transentorhinal cortex, continues to the entorhinal cortex, 
the hippocampus, amygdala and other cortical areas (Braak & Braak, 1991). The plaque and 
tangle loads are more severe in early-onset AD, and correlate in these patients with dementia 
severity (Prohovnik et al., 2006, Roth, 1986). Tangles are composed of hyperphosphorylated 
tau protein which aggregates into insoluble fibrils (Grundke-Iqbal et al., 1986, Nukina & Ihara, 
1986). Abeta is physiologically produced by the cells and is the main plaque component (Haass 
et al., 1992, Masters et al., 1985). It can accumulate due to missense mutations in amyloid 
precursor protein (APP), the precursor from which Abeta results by proteolytic cleavage by β- 
and γ-secretase (Haass & Selkoe, 1993, Kang et al., 1987, Vassar, 2001). Depending on the 
location of the mutation in the Abeta region, the production of the self-aggregating Abeta42 
peptide is enhanced, or the aggregation of Abeta is generally promoted (Ancolio et al., 1999, 
Levy et al., 1990). The duplication of the APP locus can also cause AD as a dosage effect 
(Rovelet-Lecrux et al., 2006). The most common mutations causing AD are located in the 
highly homologous presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes. Patients with 
autosomal dominant inheritance of APP and PSEN mutations have an early onset of disease 
(Levy-Lahad et al., 1995, Raux et al., 2005, Rogaev et al., 1995). Many genes have been 
proposed to affect the risk of AD, but the apolipoprotein E (APOE) ε4 allele is the most 
prevalent (Saunders et al., 1993, Strittmatter et al., 1993). Carrying one allele copy can lower 
the age of onset by about 9 years (Corder et al., 1993).  
Other hypotheses for the pathogenesis of AD have been proposed, one of them is disruption of 
mitochondrial function, which has been described in the brain of patients with AD (Blass, 
1993). The serine peptidase HTRA2/Omi is localized to the mitochondrial inter-membrane 
space and appears to modulate quality control in mitochondria as mice with a deletion of HtrA2 
have increased ROS levels, accumulation of misfolded proteins in mitochondria and die 
perinatally when HtrA2 is depleted systemically (Martins et al., 2004, Moisoi et al., 2009, 
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Suzuki et al., 2001). A connection to AD was found when HtrA2 was identified as a PSEN1 
interaction factor in a yeast two-hybrid screen (Gray et al., 2000). Moreover, APP is cleaved 
by and Abeta interacts with HtrA2 (Park et al., 2006, Park et al., 2004). HtrA2 is expressed as 
a proenzyme, which is directed to the intermitochondrial membrane where it attaches and is 
proteolytically cleaved, resulting in the soluble, mature form (Hegde et al., 2002, Kadomatsu 
et al., 2007). In response to DNA damage or other apoptotic stimuli, mature HtrA2 is released 
from the membrane into the cytosol and contributes to apoptosis (Hegde et al., 2002, Suzuki et 
al., 2001, Yang et al., 2003). 
The drug treatment of AD has been mainly symptomatic, such as affecting neurotransmitter 
levels in their availability. The implantation of cells producing neurotrophic factors into the 
brain of AD patients is a new promising treatment option which is still in its experimental phase 
(Eriksdotter-Jonhagen et al., 2012). 
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AIMS OF THE THESIS 
 
Neurodegenerative diseases involve pathological processes, which profoundly change gene 
expression profiles as well as protein and cellular functions in the brain. In addition, long-term 
treatment of these diseases influences gene expression and function. The aim of the present 
thesis was to study cellular, molecular and behavior changes, which correlate with disease 
progression using both human brain tissue and animal models of disease.  
 
The specific aims were: 
 to localize gene expression in novel genetic mouse models of Parkinson’s disease 
(papers 1, 2) 
 
 to study effects of L-DOPA treatment at behavioral and cellular levels, as well as on 
the striatal transcriptome (papers 3, 4) 
 
 to investigate gene activity and cellular localization in different brain areas affected by 
neurodegeneration in Parkinson’s disease and Alzheimer’s disease (papers 5, 6) 
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MATERIAL AND METHODS 
MATERIAL 
Human tissue samples 
Post mortem human brain tissue used for our studies was kindly provided by The Harvard Brain 
Tissue Resource Center (Belmont, USA), The Netherlands Brain Bank, the Brain Bank at 
Karolinska Institutet (Stockholm, Sweden) and the Queen Square Brain Bank for Neurological 
Disorders (London, UK). Human spleen tissue was provided by the University of Maryland 
Brain and Tissue Bank (Baltimore, Maryland, USA). Tissues were kept at -80°C until further 
use. Sections of 14 µm were used for in situ hybridization in papers IV, V and VI, and for 
immunohistochemistry in papers IV, V and VI. In papers V and VI, proteins were quantified 
using western blot, and enzyme activity was assessed in paper V. 
Rodent models of Parkinson’s disease 
In our studies we used different mouse models of PD. All mice, except for MitoPark mice in 
paper II, and mice used in paper I, were kept and bred in our animal facility. The mice were 
group housed under standardized conditions, 12 hour light/dark cycle, food and water ad 
libitum, room temperature at 21°C and 60% humidity. All experiments performed at our lab 
were approved by the Stockholm North Ethical Committee on Animal Research. 
MitoPark mice 
MitoPark mice used in papers III, IV and VI were kept and bred in our animal facility, and 
MitoPark mice used in paper II were kept and bred at the NIH, NIDA (Baltimore, Maryland, 
USA) under standardized conditions. Two mouse strains are needed for the breeding of 
MitoPark mice: DAT-/cre and TfamloxP/loxP. DAT-cre mice were created by inserting the cre gene 
into the DAT locus by multiple cloning steps. TfamloxP/loxP mice were created earlier (Larsson 
et al., 1998). Both lines are regularly backcrossed to a C57Bl6 background. MitoPark mice 
were created by Ekstrand and coworkers who crossed DAT-cre mice with mice with a loxP-
flanked Tfam allele resulting in MitoPark mice (DAT/DAT-cre TfamloxP/loxP) (Ekstrand et al., 
2007). MitoPark mice were compared to their control littermates (DAT/DAT Tfam-/loxP or 
DAT/DAT TfamloxP/loxP). In paper II mice lacking the DAT-cre construct (DAT/DAT Tfam-/- 
or DAT/DAT Tfam-/loxP) were used as control for voltammetric recordings. 
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TH-MitoPark mice 
For the assessment of electrophysiological properties of the ectopically TH expressing neurons 
in the striatum of L-DOPA treated MitoPark mice in paper IV, MitoPark mice were crossed 
with Tg(Th-EGFP)DJ76Gsat/Mmnc mice obtained from the Mutant Mouse Regional Resource 
Centers, hereafter referred to as TH-MitoPark mice. These mice were generated by injecting a 
modified bacterial artificial chromosome (BAC) into the pronuclei of FVB/N fertilized 
oocytes. The BAC containing the TH gene is modified by replacing the mRNA protein coding 
sequences by sequences encoding the eGFP reporter gene (Gong et al., 2003). Heterozygous 
mice were crossed with MitoPark mice to obtain TH-MitoPark mice (DAT/DAT-cre 
TfamloxP/loxP THeGFP+/-). These mice co-express TH and GFP in striatal neurons after L-DOPA 
treatment (Figure 1). 
 
Figure 1: Co-expression of TH and GFP in the striatum of a L-DOPA treated 
TH-MitoPark mouse. Scale bar: 20 µm 
α-Synuclein transgenic mice 
A53T α-synuclein overexpressing mice were used in paper I to study the possible interaction 
of α-synuclein and LRRK2 in the pathogenesis of PD. These mice express α-synuclein under 
the control of the mouse PrP promoter, which is hindbrain selective (previously described by 
(Lee et al., 2002)). They were backcrossed for at least ten generations and maintained on a 
C57BL76J background.  
G2019S LRRK2 and LRRK2 knockout mice 
In paper I, we studied the impact of a LRRK2 knockout (LRRK2 KO) and the overexpression 
of G2019S mutated human LRRK2 on the α-synuclein pathology in the hindbrain of a mutant 
A53T α-synuclein mouse model. The generation of LRRK2 KO mice, as well as transgenic 
mice overexpressing G2019S LRRK2, have been described previously (Andres-Mateos et al., 
2009, Ramonet et al., 2011). Briefly, the CMV-enhanced human platelet-derived growth factor 
β-chain (CMVE-PDGFβ) is driving the expression of full-length human LRRK2 containing 
the G2019S mutation. This expression is neuron-specific and includes the DA neurons in the  
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SNc. In LRRK2 KO mice, part of exon 39 and the complete exon 40, which code for the kinase 
domain, are deleted and a stop codon is inserted thereby generating LRRK2-null mice. Mice 
are maintained on a B57BL76J background. 
SynA53T/LRRK2KO and SynA53T/LRRK2G2019S mice 
For the generation of SynA53T/LRRK2KO mice, first, double mutant mice (A53T-α-
SynTg/LRRK2+/-) were generated by crossing hemizygous A53T-α-synuclein mice with 
LRRK2 KO mice. The progeny was crossed with LRRK2+/- mice to produce wild-type, 
LRRK2KO, SynA53T and SynA53T/LRRK2KO mice. Double heterozygous SynA53T/LRRK2G2019S 
mice are generated by crossing heterozygous G2019S LRRK2 and A53T-α-Syn mice. 
6-OHDA rat model 
The injection of 6-OHDA into the striatum or medial forebrain bundle is widely used to achieve 
DA depletion in striatum of rodents (Ungerstedt & Arbuthnott, 1970). Unilateral stereotactic 
injections of 6-OHDA into the striatum of rats (4.4 mm posterior and 1.2 mm lateral to Bregma 
and 7.8 mm below the dura mater) were performed under isofluoran anesthesia. At 12, 24, 48 
hours, 1 and 3 weeks after operations, rats were sacrificed by deeply sedating them with 
pentobarbital and transcardial perfusion with Lana’s fixative (4% paraformaldehyde, 14% 
picric acid in PBS). Brains were immersed in 10% sucrose solution for cryoprotection. 
METHODOLOGY 
For the study of molecular, cellular and behavioral changes we used human tissue of patients 
with AD or PD and control tissue as well as animal models of PD and controls, some of which 
received a treatment. We examined the changes with suitable techniques depending on the 
research question. Figure 2 summarizes the material and methods used in this thesis. 
 
Figure 2: Overview over the material and methods used in this thesis 
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Behavior studies 
The behavioral studies of MitoPark mice used in paper III were performed at the beginning of 
the dark period, the active phase of the circadian cycle of mice. Before each test, mice were 
habituated to the dimly-lit and noise controlled room for 60 minutes. 
Open field activity 
In paper III, we used an animal activity monitoring system (AccuScan VersaMax, AccuScan 
Instruments, Omnitech Electronics, Columbus, 
OH, USA) to detect drug-induced changes in open 
field activity. This system uses infrared-sensitive 
motion detection to record horizontal and vertical 
activity of a mouse in a Plexiglas activity chamber, 
measuring 42x42x30 cm (Figure 3). Mice were 
introduced to the chamber for 60 minutes before 
they received an injection and drug-induced 
activity was measured for 60 more minutes. The 
system collects activity data in five minute bins. 
Results were compared with two-way ANOVA 
using the GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA). 
Cylinder test 
The cylinder test is widely used for quantification of motor performance in PD. Lundblad and 
coworkers used it to quantify abnormal involuntary movements in the unilateral DA depleted 
rat after L-DOPA treatment expressed as contralateral axial, limb and orolingual movements 
(Lundblad et al., 2002). We adjusted these parameters in paper III due to the bilateral nature of 
the genetic DA depletion in the MitoPark mouse.  
Glass cylinders were placed in front of a mirror. Thirty minutes after the L-DOPA or saline 
injection, mice were placed in the cylinder and videotaped for three minutes. With the help of 
the JWatcher software (Blumstein Dt, 2006) 120 seconds in the middle of the three minutes 
were evaluated and quantified using the following behaviors: duration of rearing, number of 
times mice reared, forepaw dyskinesia, forepaw dyskinesia with turning steps, three paw 
dyskinesia, third paw wall contact, duration of rotational behavior and time spent resting. We 
defined the dyskinesia score as the sum of duration mice spent with all of the three behaviors 
forepaw dyskinesia, forepaw dyskinesia with turning steps and three paw dyskinesia. Statistical 
analysis was performed using two-way ANOVA in paper III, with treatment and treatment 
duration as variables (GraphPad Software, San Diego, CA, USA). 
Figure 3: The AccuScan VersaMax 
system was used to assess locomotor 
activity of mice 
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Gait analysis 
In MitoPark mice we measured gait parameters under voluntary and forced gait conditions 
before and after treatment. For the voluntary analysis we used the CatWalk System (Noldus 
Information Technology, Netherlands) which consists of a glass runway, a light bulb and a 
LCD camera (Figure 4). Paw placements are recorded by light, which escapes the plate when 
a paw is placed on the plate. Assessment of forced 
gait was performed on the TreadScan system 
(CleverSys Inc., Reston, VA, USA). Paw 
placements, which are detected by a LCD camera, are 
later analyzed by color differences from fur to paw. 
The following gait parameters were analyzed with 
the two systems if more than 11 consecutive steps 
were performed: base of support (BOS, average 
widths between either fore- or hind paws), stride 
length (distance between successive placements of 
the same paw) and swing speed (speed of the paw 
during the swing phase). Results were compared 
using Student’s t-test (GraphPad Software, San 
Diego, CA, USA).  
Immunohistochemistry and Western blot 
Immunohistochemistry and Western blot are used for the detection of proteins. 
Immunohistochemistry allows cellular localization of proteins and Western blot the 
quantification of protein expression in tissues.  
In papers III, IV and VI we performed immunohistochemistry on perfusion fixated rodent 
tissue, as well as post-fixated and fresh frozen human brain tissue. 
Cryoections of 14 µm thickness were cut and mounted on slides (Superfrost Plus slides, VWR 
International AB, Sweden). The primary antibody was applied over night at 4°C and the 
respective secondary antibody for two hours at room temperature. For light microscopical 
visualization, the principle of avidin-biotin binding (ABC kit, Vectastain) followed by 
incubation with the chromogen substrate diaminobenzidine (Sigma Aldrich), as well as a 
nuclear counterstain with cresylviolet was used. For subcellular co-localization studies 
fluorescent labeled secondary antibodies with specific excitation and emission spectra were 
applied. 
Western blots were used to quantify MPO expression in human brain tissue. Equal amounts of 
proteins were separated on a denatured gradient polyacrylamide gel and transferred to a 
polyvinylidene fluoride membrane. The membranes were blocked with non-fat milk and 
Figure 4: The Noldus® CatWalk ST 
system was used to perform voluntary 
gait analysis. Courtesy Noldus 
Information Technology BV 
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incubated with the first antibody over night at 4°C. The specific antibody binding was 
visualized with a fluorophore coupled secondary antibody. The pixel density of the bands was 
measured with the freeware program Image J (Schneider et al., 2012). 
In situ hybridization 
Oligonucleotide probes used for in situ hybridization (Good et al., 2011, Westerlund et al., 
2008) were designed in ApE v1.13 developed by M. Wayne 
(http://biologylabs.utah.edu/jorgensen/wayned/ape/). The primers were designed to be 49 to 51 
bases long, the melting temperature set to 72-76° and the GC content at 40-60% (Thermo 
Scientific, Ulm, Germany). Probes having a folding energy <-4 kcal/mol were selected and 
their sequence specificity was compared to the NCBI reference library 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
In situ hybridization with radioactive labeled probes was used in papers I, II, III, IV, V and VI. 
With this method the mRNA expression in tissue can be visualized and quantified on film or 
microscopically analyzed if the slides are dipped in photographic emulsion. For in situ 
hybridization 14 µm sections of fresh frozen rodent or human tissue were used. Oligonucleotide 
probes were 3’ labeled with 32P-deoxyadenosine 5’-triphosphate using terminal 
deoxynucleotidyl transferase (Fermentas, VWR), cleaned and concentrated (ProbeQuant G-50 
Micro Columns, GE Healthcare). The labeled probes were hybridized to the tissue over night 
at 42°C, washed in SSC and H2O under highly stringent conditions and dehydrated using 
increasing concentrations of ethanol. The signal intensity was estimated using phosphoimaging 
plates (BAS reader 3000 system, Fujicolor Sverige AB) before exposure to autoradiographic 
film (BioMax MR Film, Eastman Kodak) or dipping in photographic emulsion (NTB2 
solution, Carestream Health Inc., VWR) and developed after appropriate exposure time. For 
statistical analysis Student’s t-test was performed in papers II, III and IV (GraphPad software 
version 5, GraphPad, San Diego, CA, USA). 
RNA extraction and qRT-PCR 
Total RNA was extracted from frozen tissue using a tissue homogenizer and trizol. 
Complementary deoxyribonucleic acid (cDNA) was synthesized (SuperScript III First-Strand 
Synthesis System, Life Technologies) and the abundance was measured (Sybr Green, Applied 
Biosystems) on a QuantStudio 6 qRT-PCR system (Applied Biosystems). Primer pairs with 
products of 120 to 150 bp were chosen when they had a ~100% efficiency and gave a single 
product on the dissociation curve. Quantitative RT-PCR was used in paper IV for the validation 
of RNA-Sequencing (RNA-Seq) data. We used Ppid as housekeeping gene. Statistical analysis 
was performed using one-way ANOVA (GraphPad Software, San Diego, CA, USA). 
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RNA sequencing 
RNA-Seq is a high throughput method for the comparison of the transcriptome between study 
groups. It can also detect and quantify different splice variants and RNA editing of changes in 
expression levels. We used this method in paper IV to compare changes in expression levels in 
control and MitoPark mice treated chronically with either saline or L-DOPA. To perform this 
technique, the striatum was lysed, total RNA extracted with Trizol and a tissue douncer, 
messenger RNA pulled down with oligo(dT) priming and transcribed into cDNA (see figure 
6). Adaptors are ligated to the cDNA to be able to attach them to the matrix on the flow cell 
where they are multiplied into clusters of the same sequence using PCR. Six libraries are pooled 
and hybridized to a lane with 100-bp paired end sequences. For the analysis of the sequence, 
fluorescently labeled nucleotides and a polymerase are added. The nucleotides are blocked at 
the 3’ group so that only one nucleotide can be incorporated in one run. The incorporated 
nucleotides are imaged and give a signal for each cluster of cDNA sequences bound to the cell, 
and then another round is started with the addition of nucleotides and the polymerase, stepwise 
building the new strand of DNA. The order of nucleotides at each cluster is compiled from the 
fluorescent signal of the spot at each step, and all sequences are identified by annotation to the 
mouse reference genome. Several programs were used to align the sequences, for annotation 
and normalization. RNA-Seq has advantages over microarray in gene expression 
quantification. It does not rely on probe design and therefore novel genes can be detected. The 
dynamic range is bigger than that of microarrays and results are more closely related to absolute 
protein expression levels than microarray results (Fu et al., 2009, Ning et al., 2012, T Hoen et 
al., 2008). 
Figure 5: Representative 
standard amplification curves in 
a qRT-PCR run. 
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Figure 6: Schematic presentation of the RNA-Seq steps. Adapted from (Van Der Brug 
et al., 2010) and (Mardis, 2008). 
 
Electrophysiology 
Electrophysiological measurements were used in paper IV to characterize TH expressing cells 
in striatum of L-DOPA treated TH-MitoPark mice. TH expressing cells were visualized by 
their eGFP expression using IR-DIC microscopy. To perform the measurements, brains were 
sliced in ice-cold extracellular solution, kept at 35°C for 30 minutes, and moved to room 
temperature before recordings. Recordings were performed at a temperature of 35°C. GFP 
fluorescent neurons were patched and identified by their passive and active membrane 
responses to step and ramp current injections. The current injections were chosen stepwise and 
started with an initial near-threshold step pulse to capture key active and passive properties to 
identify the cell type (Wang et al., 2004). 
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RESULTS 
MOUSE MODELS OF PD 
Interaction of LRRK2 and α-synuclein, paper I 
Polymeropoulos and coworkers discovered and mapped the first gene found in familial PD, α-
synuclein (Polymeropoulos et al., 1997). The disease causing mutation was an exchange of 
alanine on position 53 to threonine leading to fibrillization and accumulation of the protein in 
LBs in DA neurons of the SNc, a pathological characteristic of PD (Spillantini et al., 1997). A 
few years later LRRK2 was mapped to chromosome 12 and six disease-causing mutations were 
discovered in different domains of the protein (Funayama et al., 2002, Paisan-Ruiz et al., 2004, 
Zimprich et al., 2004). The most common mutation is the exchange of glutamine on position 
2019 to serine in the kinase domain, leading to an increase in kinase activity, which causes 
toxicity and increased neurodegeneration (Smith et al., 2006, West et al., 2007). In the brains 
of PD patients harboring the G2019S LRRK2 mutation LBs are a common pathological 
finding, which led to the hypothesis of a possible interaction of these two proteins during the 
development of PD. 
In paper I we studied the possible interaction between LRRK2 and α-synuclein by using 
transgenic mouse lines. The already well established mouse model with A53T α-synuclein 
under the control of the hindbrain-selective prion protein promoter was crossed with mice with 
a knockout of endogenous LRRK2 or overexpression of human G2019S mutant LRRK2 (Lee 
et al., 2002, Von Coelln et al., 2006). To characterize the expression patterns of the transgenic 
proteins we performed in situ hybridization of brain tissue sections from the different 
transgenic mouse lines. Both the A53T-α-synuclein and the G2019S-LRRK2 transgenes were 
broadly expressed in brain areas affected by neurodegeneration and were co-expressed 
throughout the brain at 9 and 12 months of age. The impaired acoustic startle response of A53T-
α-synuclein mice was not changed by LRRK2 deletion or overexpression, neither was the 
premature lethality of these mice. At 13 to 14 months of age, the abnormal accumulation of 
phosphorylated human α-synuclein in the brainstem was modestly reduced in the absence of 
LRRK2 and slightly increased by the presence of human G2019S-LRRK2 overexpression, 
analyzed with a specific antibody against the pathological form of human α-synuclein. Glial 
fibrillary acidic protein (GFAP), a marker for astrocytes, was increased in the reticular 
formation and in the SNc in end-stage A53T-α-synuclein mice, whereas a marker for microglia, 
Iba1, was not affected by LRRK2-G2019S or LRRK-KO. Also the neuron numbers in the SNc 
stained for TH and Nissl were not changed by the modulation of LRRK2 expression. The 
results reported in this study do not support the hypothesis that LRRK2 expression influences 
A53T-α-synuclein pathology in the hindbrain.  
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Neurobiological events in the premotor phase of PD in the MitoPark 
mouse, paper II 
The onset of motor symptoms in MitoPark mice begins at around 12 weeks of age, when the 
number of DA neurons in the SNc of the mice is approximately 40 percent reduced. In paper 
II we studied the neurochemical and electrophysiological properties in MitoPark mice aged 6 
to 8 weeks, before the onset of motor impairment. Whole-cell patch-clamp recordings were 
performed on SNc neurons to assess the hyperpolarization-activated cation current Ih, which is 
an electrophysiological marker of SNc DA neurons mediated by hyperpolarization-activated 
cyclic nucleotide-gated (HCN) ion channels (Lacey et al., 1989). HCN channels mediate Ih 
current in response to membrane hyperpolarization. 
DA neurons of MitoPark mice had a smaller Ih amplitude and a reduction in the maximum 
hyperpolarization-activated cation conductance compared to control mice. In a next step we 
examined by in situ hybridization if the reduced Ih resulted from a reduced expression of HCN 
channels and if the voltage dependence of the remaining pool of functional HCN channels was 
changed. The mRNA expression levels of the four known isoforms of the HCN gene were 
compared in MitoPark mice at the ages of 6, 10 and 21 weeks with two oligonucleotide probes 
per isoform. HCN2 and 3 were strongly expressed in the SNc and VTA of MitoPark and control 
mice and the expression did not differ between the ages or genotypes analyzed (Figure 7). 
HCN1 and 4 were only weakly expressed in this area.  
 
Figure 7: HCN1-4 mRNA expression on the level of the SN of a 10-week-old MitoPark 
mouse. Figure adapted from paper I, Good et al. FASEB J. 2011 Apr;25(4):1333-44 
 
Current clamp recordings detected three different groups of SNc DA neurons, with one group 
of neurons having similar properties as the neurons in control mice. The other groups had 
divergent electrophysiological properties, which may represent increasing states of cellular 
disturbance in young MitoPark mice before the onset of motor impairment. These differences 
in MitoPark mice led to the assumption that there might be an altered striatal DA release. HCN 
channels are sensitive to levels of cyclic adenosine monophosphate (cAMP). An increase of 
Ca2+ in DA SNc cells in MitoPark mice, due to the mitochondrial failure, may lead to reduced 
cAMP levels, thereby decreasing HCN channel gating (Chan et al., 2007). In vivo 
microdialysis in the dorsal striatum of control and MitoPark mice did not show a significant 
difference in the extraction fraction of DA or the basal extracellular concentration. However, 
the perfusion stimulated overflow of DA was significantly reduced in MitoPark mice. The DA 
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uptake mediated by DAT was unchanged in striatum of MitoPark mice but the vesicular DA 
release was reduced at the age of 6 to 8 weeks. Taken together, early physiological changes 
due to the mitochondrial failure in DA neurons are detectable long before overt behavioral 
deficits. Similar modifications are likely to happen in PD patients many years before the disease 
is diagnosed, and MitoPark mice are likely a promising model to investigate the initial neuronal 
changes during the early, pre-clinical stage of PD. 
Establishment of MitoPark mice as a dyskinesia model, paper III 
The aim of this study was the establishment of MitoPark mice as a genetic bilateral dyskinesia 
model. We used MitoPark mice at three different stages of DA depletion to study bilateral 
changes in motor behavior after chronic treatment with a moderate, clinically relevant dose of 
L-DOPA. Long-term treatment produced an age-dependent increase in locomotor activity and 
a normalization of gait parameters compared to control levels. Stride length as well as swing 
speed were increased in chronically treated compared to saline treated MitoPark mice after 
long-term treatment as studied using both, voluntary and forced gait analysis systems. Two 
days of treatment did not induce dyskinetic behavior, measured as the sum of the durations of 
forepaw dyskinesia, forepaw dyskinesia with turning steps and three paw dyskinesia.  
 
 
Eleven days of L-DOPA treatment induced an age-dependent increase in time of these bilateral 
behaviors in MitoPark mice. Saline treated MitoPark mice did not exhibit dyskinetic behavior 
but were rather immobile. No increase in activity was detected when control mice were 
chronically treated with L-DOPA. The expression of striatal FosB and prodynorphine was only 
increased in L-DOPA treated MitoPark mice.  
Taken together, we showed that MitoPark mice have DA-depletion and treatment dependent 
changes in behavioral and biochemical measurements. The side effects of the treatment 
resemble those seen after the long-term L-DOPA treatment in PD patients, suggesting that the 
MitoPark mouse may serve a useful genetic and bilateral model for the study of drugs against 
LID. 
Figure 8: Dyskinesia score. Sum of the 
durations of forepaw dyskinesia, 
forepaw dyskinesia with turning steps 
and three paw dyskinesia of chronically 
saline (open circle) and L-DOPA (grey 
circle) treated MitoPark mice. The 
dyskinesia score of control mice is 
displayed as black triangle. Figure 
adapted from Gellhaar et al. Genes 
Brain Behavior 2015. 
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TH expressing cells in the striatum of MitoPark mice after L-DOPA 
treatment, paper IV 
In paper IV we studied the effect of chronic L-DOPA treatment on the transcriptome, protein 
expression and on electrophysiological properties of the striatum in a rodent PD model, the 
MitoPark mouse. The gene with the highest differential expression, as measured by RNA-Seq 
in the striatum after chronic L-DOPA treatment in MitoPark mice, was TH. Notably, L-DOPA 
did not induce expression of TH in striatum of control mice. We also found TH protein in cells 
of L-DOPA treated MitoPark mice, but did not detect any TH protein expressing cells in 
chronically saline or L-DOPA treated control mice, and just few in saline treated MitoPark 
mice. The induction of TH was DA depletion and L-DOPA dose dependent, as assessed by one 
and three days of treatment. Discontinued L-DOPA treatment reversed the expression of TH. 
An example of dose dependency for TH induction is shown in figure 9 in 20-week-old 
MitoPark mice.  
 
Markers of interneurons, such as calretinin, neuronal nitric oxide synthase (nNOS), glutamate 
decarboxylase, 67 kDa (GAD67) and parvalbumin colocalized with TH expression in striatum 
of chronically L-DOPA treated MitoPark mice. Many dopamine- and cAMP-regulated 
phosphoprotein, 32 kDa (DARPP-32) immunoreactive (ir) medium spiny neurons were 
detected, but this expression pattern was never colocalized with TH expression. A co-
expression with aromatic L-amino acid decarboxylase (AADC) indicates that the TH positive 
cells could produce DA. 
By crossing MitoPark mice with mice expressing eGFP under the TH promoter, we generated 
TH-MitoPark mice. After L-DOPA treatment, eGFP expressing neurons in striatum were 
studied by electrophysiology which confirmed an interneuronal nature of these cells. In a next 
step we analyzed the relevance of these findings in human postmortem striatal tissue and 
detected an increase of TH mRNA expression in putamen and caudate nucleus of PD patients 
compared to neurologically healthy controls. This study demonstrates the induction of a 
subpopulation of TH ir neurons in the DA depleted striatum following L-DOPA treatment and 
MitoPark mice may be useful for further studies of the molecular effect of these TH ir neurons 
in the course of L-DOPA treatment. 
Figure 9: Increasing doses of L-DOPA 
induce an increasing number of TH ir cells 
in MitoPark mice (grey circles). 20-week-
old animals were daily treated with 2, 8, or 
16 mg/kg of L-DOPA for three weeks. 
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NEURODEGENERATIVE DISEASE PATHOLOGY IN HUMANS 
Analysis of the expression and activity of HTRA2 in AD and PD, paper 
V 
The HtrA serine peptidase 2 (HTRA2) is localized in the mitochondrial intermembrane space 
and can mediate cell death following apoptotic stimuli by exposition of an inhibitor of apoptosis 
protein (IAP) binding motif or via its serine protease activity (Suzuki et al., 2001). An N-
terminal signal targets the precursor to the mitochondrial intermembrane space where it is 
cleaved to the proteolytically active form (Gray et al., 2000). In 2005, the autosomal dominant 
mutations G399S and the A141S mutant allele in the HTRA2 gene were found in German PD 
patients (Strauss et al., 2005). The resulting defect in protease activity led to an altered 
mitochondrial morphology and made cultured cells more susceptible to stress-induced cell 
death (Strauss et al., 2005). Implication in AD was evidenced by the interaction of HTRA2 
with Abeta, inducing neuronal apoptosis (Park et al., 2004).  
In paper V we studied the protein expression and enzymatic activity of HTRA2 as well as the 
mRNA expression in AD patient material. The HTRA2 variants A141S and G399S were 
analyzed in a Swedish case-control material for AD and PD. Protein quantification by Western 
blot revealed a significant decrease of the active form of HTRA2 in frontal cortex samples from 
AD cases, but unchanged levels of the unprocessed form. Unexpectedly, proteolytic activity of 
HTRA2 was significantly increased when compared to control tissue. Messenger RNA 
expression in frontal cortex samples indicated a slight non-significant reduction in AD tissue 
measured with two probes targeting different exons. The HTRA2 mRNA expression in the 
dentate gyrus was unchanged compared to control tissue. As expected, GFAP mRNA levels 
were significantly increased and UCH-L1 mRNA levels were significantly decreased in frontal 
cortex and hippocampus samples of AD compared to control tissue. The A141S variant was 
weakly associated with respect to genotype and allele frequencies between AD and controls, 
but not for PD and controls. The G399S mutation was absent in the Swedish AD case-control 
material and in the PD material no differences in genotype or allele frequencies were detected 
between PD and control samples. The unchanged levels of HTRA2 mRNA and of the 
unprocessed protein in the frontal cortex of AD patients suggest that pathological changes 
occur on posttranslational levels, as strengthened by the significant decrease of the active form 
in AD tissue. This could possibly be due to increased degradation, although the increase of 
enzymatic activity does not support such a hypothesis. Also, the disease associated mutations 
have been reported to decrease protease activity (Strauss et al., 2005). This is not in line with 
our results, as one of the AD specimens contained the A141S variant, but the expression levels 
and protease activity did not differ from the other AD brain samples. Previous studies measured  
 
 
 
 28 
the enzyme activity in vitro, which indicates that other factors, for example other genetic 
variants, influence the enzyme activity. For example, Plun-Favreau and coworkers reported 
that PINK1, the PARK6 gene, interacts and phosphorylates HTRA2 and that mutations in 
PINK1 lead to decreased phospho-HTRA2 levels (Plun-Favreau et al., 2007). 
Myeloperoxidase-expressing cells in affected brain regions in AD and 
PD, paper VI 
Oxidative stress has been implicated in the pathogenesis of several neurodegenerative diseases. 
Phagocytes, macrophages and microglia constitute a major source of oxidants. They generate 
these with enzymes, such as MPO. This enzyme produces HOCl, and the levels of MPO have 
previously been reported to be increased in AD and PD brain samples (Choi et al., 2005, Green 
et al., 2004). 
We analyzed the same human tissue samples with Western blot, immunohistochemistry and in 
situ hybridization for the expression of MPO. Western blot detected not only the bands for 
MPO, as assessed by human spleen lysate, but further bands with higher and lower molecular 
weight. Quantification of the band with high molecular weight showed an increased amount of 
MPO protein in PD striatum samples compared to control samples. Immunohistochemistry 
revealed MPO ir cells, which were small with a round or elongated shape (Figure 10).  
 
These cells were also detected in the wall of larger blood vessels as well as in or around amyloid 
plaques in brain tissue from AD patients. The size and shape suggested these to be blood-
derived cells, such as monocytes or macrophages, and not astrocytes or neurons. Binding to 
pyramidal neurons in the hippocampal CA1 region was most likely unspecific binding to 
modified proteins. In two rodent models of PD, the 6-OHDA rat and the MitoPark mouse, 
MPO ir was not detected in cells of the brain. Furthermore, MPO mRNA was not detected in 
human or rodent brain tissue, neither were hypochlorous acid modified proteins.  
We conclude that MPO protein expression is significantly increased in hippocampus and 
frontal cortex of AD patients and in striatum and SNc of PD patients, brain areas specifically 
affected by the two forms of neurodegeneration, respectively. These results suggest that 
inhibitors of MPO might be useful in the treatment of AD and PD. 
Figure 10: MPO ir cells (small 
brown and with a brown halo) 
located in close proximity to DA 
neurons (large cell filled with 
greyish neuromelanin granules) 
in the SNc of a PD patient. Scale 
bar: 25 µm. 
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GENERAL DISCUSSION 
The pathology of neurodegenerative diseases can be studied in human postmortem tissue and 
in animal models, which increase our understanding about the causes and possible treatment 
options of the disease. In studies presented in this thesis, we examined different animal models 
of PD and where possible, tried to validate these findings in human postmortem tissue.  
The earliest animal models of PD were toxin induced models, which reproduce key motor 
symptoms and a fast degeneration of DA neurons. Even though different degrees of DA 
depletion can be achieved by different injection regimens, the slow development of DA cell 
death occurring in PD is difficult to reproduce. With genetic models such as the MitoPark 
mouse we are able to model the effects of progressive degeneration from pre-symptomatic to 
late stage PD in a time-frame of about eight months. That gives the possibility to study 
treatments and molecular changes at different stages of disease. We detected for example in 
young MitoPark mice an altered function of the hyperpolarization-activated cation current, 
which was not caused by altered mRNA expression of the four HCN channels. This reduced 
pacemaker activity of DA neurons in presymptomatic PD stages had not been demonstrated 
before and gives valuable information about pathological processes in human brain, long before 
DA neurons degenerate. At an older age MitoPark mice can be used to study treatment effects 
on behavioral and molecular level in order to improve the therapy of late stages of PD. Daily 
treatment with L-DOPA induced progressive LID in MitoPark mice and the induction of TH 
expressing cells in the striatum, changes that can also be detected in PD patients. We 
established the conditions to use MitoPark mice as a new, toxin-free LID model, in which novel 
anti-dyskinetic drugs can be tested to reduce the side effects of L-DOPA treatment. 
Although rodent models show many of the PD symptoms, some features are not reproduced. 
The immunological components in neurodegenerative diseases are very difficult to study in 
models because they are seldom present. A good example is the increase of MPO ir blood-
derived cells detected in disease affected regions in AD and PD cases which we failed to find 
in several mouse and rat models of disease. 
The discovery of genetic causes of PD led to the development of transgenic animal models for 
the study of cellular changes caused by a mutation. The results found in cell culture do often 
not match those found in animal models and complicate the interpretation of the “real effect” 
of the mutation. Cell culture experiments showed that knockdown of LRRK2 induced an 
increased number of small LBs in cells with α-synuclein inclusion formation (Guerreiro et al., 
2013). Our results in transgenic mouse models failed to reproduce this finding. The 
introduction or ablation of LRRK2 together with mutated human α-synuclein in a PD mouse 
model did not result in altered aggregation of LBs, although both genes were expressed in the 
same brain area. 
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To date, animal models have been helpful in modeling PD and AD pathology, although all 
models have their limitations. Toxin-induced degeneration models the symptoms but does not 
reveal the cause of PD. Overexpression and knockout of disease-implicated genes and cell-
specific ablation of e.g. the transcription factor Tfam in mouse models have increased our 
understanding of pathological mechanisms. However, we need to keep in mind that the 
expression of human mutated genes in animal models might induce a mismatch between the 
human and animal protein functions and pathways. In addition, all findings in animal models 
need to be validated and confirmed in human cases. One important limitation of analyzing 
human brain material is that we can study only a given time point, while we can study many 
pathways with various sophisticated methods in animal models. Yet, we need to keep in mind 
that only the comparison of results from animal models with human findings will lead to the 
development of better animal models that more closely resemble the human disease. 
The use of animal models of diseases complements the analysis of post-mortem tissue from 
patients with neurodegenerative diseases in the effort to understand the underlying pathological 
mechanisms. Promising recent advancement has been made in the discovery of predictive 
biomarkers for early stages of disease, in order to find treatments to halt degeneration before 
irreversible damage occurs in the brain. Nevertheless, finding the cause (or causes) of 
neurodegeneration will remain a major research challenge. 
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CONCLUSIONS 
We used a variety of mouse lines to model specific pathological or genetic findings reported in 
Parkinson’s or Alzheimer’s disease. Where possible, we corroborated our results in follow up 
analyses of human brain samples.  
 In transgenic mouse models with overexpression or knockout of the PARK genes α-
synuclein and LRRK2 we mapped the expression patterns of the transgenes. Although they 
were expressed in the same brain areas including the brain stem, we detected no influence 
on the number of DA neurons and α-synuclein pathology was largely independent of the 
presence of LRRK2, indicating separate pathological pathways. 
 In young MitoPark mice, before the onset of motor symptoms, electrophysiological studies 
demonstrated that the pacemaker function and the neurotransmitter release was impaired. 
We studied the expression of HCN1-4 channels necessary for the pacemaker activity and 
did not detect any difference in mRNA expression levels in SNc compared to control mice, 
indicating post-translational adaptations. The study revealed striking dysfunctions of the 
nigrostriatal circuits in presymptomatic animals and provides a good animal model for early 
phases of PD. 
 In middle aged and old MitoPark mice we demonstrated that chronic L-DOPA treatment 
normalized gait parameters, but also induced hyperactivity and dyskinetic movements in a 
DA-depletion dependent way. We established the requirements to use MitoPark mice as 
dyskinesia model and demonstrated the induction of dyskinesia markers in the striatum. 
This animal model of late phases of PD will probably be very useful to detect novel 
therapeutic targets to counteract L-DOPA induced adverse effects. 
 In a further study on the effects of chronic L-DOPA treatment on striatal neurons in 
MitoPark mice we established that the induction of TH mRNA is one of the most robust 
effects on the transcriptome. We showed that TH was induced in neurons with histological 
and electrophysiological characteristics of striatal interneurons, and that the induction was 
dependent on the degree of DA depletion and the dose of L-DOPA. The TH induction in 
the mouse model was validated in human samples where we reported increased mRNA 
levels in putamen and caudate nucleus of PD cases. 
 In human DNA and brain samples from AD or PD cases and matched controls we analyzed 
alterations in allele frequencies and gene activity of the mitochondrial serine peptidase 
HTRA2. In frontal cortex and hippocampus of AD cases we detected unaltered HTRA2 
mRNA levels, whereas the level of the processed protein was significantly decreased and 
the enzymatic activity increased in frontal cortex samples from AD cases. In addition we 
discovered a weak association of one allele with AD, but not with PD, further supporting an 
involvement of this gene in neurodegeneration. 
 In several brain areas affected by neurodegeneration in AD and PD we detected an increased 
number of MPO ir cells with the size and shape of blood-derived monocytes / macrophages. 
In our PD animal models these cells were not detected. Our results support a role for an 
inflammatory process in AD and PD and the study of anti-inflammatory treatments. 
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